Compare Mesoblast Limited (MESO) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Koninklijke Philips NV — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Koninklijke Philips NV trades at $24.38 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 13.4× Mesoblast Limited's market cap, and Koninklijke Philips NV pays a 4.17% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Koninklijke Philips NV for 84 Days on average.
| MESO | PHG | |
|---|---|---|
Market Cap | $1.75B | $23.52B |
Volume | 239,027 | 1,635,069 |
Sector | Health | Health |
52-Week High | $20.96 | $32.91 |
52-Week Low | $13.19 | $23.81 |
Typical Hold Time | 14 Days | 84 Days |
Enterprise Value | $1.83B | $29.87B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
PHG trades at $24.09, down 0.25% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Recent news highlights product innovations including new CT systems and AI healthcare tools, while institutional investors like Bank of America and Arrowstreet Capital have increased positions.
PHG presents a mixed outlook with solid profitability recovery but technical weakness. The stock offers value at reasonable valuations (P/E 18.84, P/S 1.18) and analyst consensus leans Hold (63.64%). Key risks include cybersecurity threats (Reuters, 2026-08-13) and debt levels, while opportunities lie in healthcare technology expansion and Exor's potential increased stake to 22% (Reuters, 2026-08-11).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
